Oric Pharmaceuticals (ORIC)
(Delayed Data from NSDQ)
$9.16 USD
+0.14 (1.55%)
Updated May 17, 2024 04:00 PM ET
After-Market: $9.15 -0.01 (-0.11%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Brokerage Reports
Oric Pharmaceuticals, Inc. [ORIC]
Reports for Purchase
Showing records 1 - 20 ( 53 total )
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Looking Forward to ORIC-944 Results; 4Q23 Financials Reported; Raising PT to $21
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ORIC-944 Movin'' on to Combos; ''114 on Course
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ORIC-533 Could Emulate Nirogacestat''s Clinical Path; Modulating PT to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ORIC-533 Looking for Someone Under the Mistletoe
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Initial ORIC-533 Results Expected at ASH; 3Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Gettin'' Ready to Make a Splash at ASH; Prostate Exam Next Year
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ASH 2023 Abstract Round Up for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Initial ORIC-114 Results Impress, in Our View; Raising PT to $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ORIC-114 Inserting Into the EGFR/HER2 Landscape
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D